Click
here to close Hello! We notice that
you are using Internet Explorer, which is not supported by Echinobase
and may cause the site to display incorrectly. We suggest using a
current version of Chrome,
FireFox,
or Safari.
Proc Natl Acad Sci U S A
2019 Jun 04;11623:11428-11436. doi: 10.1073/pnas.1902651116.
Show Gene links
Show Anatomy links
Genomic correlates of clinical outcome in advanced prostate cancer.
Abida W
,
Cyrta J
,
Heller G
,
Prandi D
,
Armenia J
,
Coleman I
,
Cieslik M
,
Benelli M
,
Robinson D
,
Van Allen EM
,
Sboner A
,
Fedrizzi T
,
Mosquera JM
,
Robinson BD
,
De Sarkar N
,
Kunju LP
,
Tomlins S
,
Wu YM
,
Nava Rodrigues D
,
Loda M
,
Gopalan A
,
Reuter VE
,
Pritchard CC
,
Mateo J
,
Bianchini D
,
Miranda S
,
Carreira S
,
Rescigno P
,
Filipenko J
,
Vinson J
,
Montgomery RB
,
Beltran H
,
Heath EI
,
Scher HI
,
Kantoff PW
,
Taplin ME
,
Schultz N
,
deBono JS
,
Demichelis F
,
Nelson PS
,
Rubin MA
,
Chinnaiyan AM
,
Sawyers CL
.
???displayArticle.abstract???
Heterogeneity in the genomic landscape of metastatic prostate cancer has become apparent through several comprehensive profiling efforts, but little is known about the impact of this heterogeneity on clinical outcome. Here, we report comprehensive genomic and transcriptomic analysis of 429 patients with metastatic castration-resistant prostate cancer (mCRPC) linked with longitudinal clinical outcomes, integrating findings from whole-exome, transcriptome, and histologic analysis. For 128 patients treated with a first-line next-generation androgen receptor signaling inhibitor (ARSI; abiraterone or enzalutamide), we examined the association of 18 recurrent DNA- and RNA-based genomic alterations, including androgen receptor (AR) variant expression, AR transcriptional output, and neuroendocrine expression signatures, with clinical outcomes. Of these, only RB1 alteration was significantly associated with poor survival, whereas alterations in RB1, AR, and TP53 were associated with shorter time on treatment with an ARSI. This large analysis integrating mCRPC genomics with histology and clinical outcomes identifies RB1 genomic alteration as a potent predictor of poor outcome, and is a community resource for further interrogation of clinical and molecular associations.
Fig. 1. Overview of sample and patient characteristics for 444 tumors from 429 patients with mCRPC. (A) Site of mCRPC tumors profiled. (B) Histopathologic classification of profiled tumors. Tumors were classified by central review as adenocarcinoma, pure small-cell/neuroendocrine cancer, adenocarcinoma with neuroendocrine features (also included mixed acinar/neuroendocrine carcinoma), or could not be classified due to scant material or no tumor visible on the slides that were available for review despite successful sequencing. (C) Patient exposure status to next-generation AR signaling inhibitors (abiraterone acetate, enzalutamide, or ARN509) and to taxanes at the time of biopsy for the 444 profiled tumors. (D) Overall survival (OS) from the date of biopsy of the profiled tumor. OS was longer for tumors from ARSI- and taxane-naive patients compared with patients who had received an ARSI before the biopsy (P < 0.01, log-rank test). Survival was shortest when the patient had received both an ARSI and taxane chemotherapy at the time of biopsy.
Fig. 3. Alteration in PI3K and homologous recombination repair genes and association with clinical outcomes. (A) Oncoprint of genomic alterations in PI3K pathway genes. (B and C) Kaplan–Meier analysis showing overall survival (B) and time on treatment with a first-line ARSI (C) in PI3K pathway altered (red) versus unaltered (black) tumors. (D) Oncoprint of genomic alterations in BRCA2, BRCA1, and ATM. (E) Kaplan–Meier analysis showing time on treatment with a first-line ARSI in BRCA2/1/ATM–altered (homozygous deletion or somatic or pathogenic germline mutation) (red) versus unaltered (black) tumors.
Fig. 4. Androgen receptor alterations and outcome. (A) AR splice variant landscape. LBD, ligand binding domain. (B) AR pathway expression score in AR-amplified (n = 168) versus nonamplified (n = 159) tumors. ***P < 0.001. (C) AR amplification frequency in ARSI-naive versus exposed tumors. (D) Kaplan–Meier analysis showing time on treatment with a first-line ARSI in AR-amplified versus nonamplified tumors. (E) Association between ARV7 expression and time on treatment with a first-line ARSI. o, censored event; x, off-treatment event.
Fig. 5. Integrative analysis incorporating histopathology, transcript-based assessment of AR signaling and NEPC score, TP53 and RB1 genomic status, and clinical outcomes. (A) Kaplan–Meier analysis showing overall survival from the start of a first-line ARSI versus genomic status for TP53 and RB1 in n = 128 patients who received a first-line ARSI and underwent tissue profiling at baseline (before or within 90 d of therapy start). (B and C) Kaplan–Meier analysis showing time on treatment with a first-line ARSI by genomic status for RB1 and TP53. P values were generated from the log-rank statistic. (D) Frequency of histopathologic neuroendocrine features in pre- versus post-ARSI samples, among patients who received an ARSI at some point during their treatment history. Patients who were not reported to have received an ARSI at any point were excluded. **P < 0.01. (E) NEPC expression score in pre- (n = 118) versus post- (n = 152) ARSI samples, as in D. NS, not significant. (F) AR and NEPC expression scores, histopathology (CRPC-Adeno, no NE features; CRPC-NE, histopathologic NE features) and TP53/RB1 genomic status (circle, wild type for both; diamond, both altered) for the 332 tumors with RNA-sequencing data. Ten cases (3%, blue box) had low AR and low NEPC expression scores. (G–J) Representative cases of CRPC-Adeno (G), CRPC-NE, small-cell type (H), CRPC-Adeno showing intermediate transcriptomic scores (I), and CRPC-Adeno showing a high NEPC score/low AR signaling score (J). Tumors represented in I and J were noted to have distinct nuclear features, including various degrees of nuclear pleomorphism, irregular nuclear membrane contours, and/or high mitotic activity. (Scale bars, 25 μm.)
Abida,
Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making.
2017, Pubmed
Abida,
Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making.
2017,
Pubmed
Abida,
Targeting DNA Repair in Prostate Cancer.
2018,
Pubmed
Aggarwal,
Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study.
2018,
Pubmed
Annala,
Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer.
2018,
Pubmed
Antonarakis,
AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.
2014,
Pubmed
Aparicio,
Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers.
2016,
Pubmed
Armenia,
The long tail of oncogenic drivers in prostate cancer.
2018,
Pubmed
Barbieri,
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer.
2012,
Pubmed
Beltran,
Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets.
2011,
Pubmed
Beltran,
Aggressive variants of castration-resistant prostate cancer.
2014,
Pubmed
Beltran,
Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer.
2016,
Pubmed
Beltran,
A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers.
2019,
Pubmed
Blattner,
SPOP Mutation Drives Prostate Tumorigenesis In Vivo through Coordinate Regulation of PI3K/mTOR and AR Signaling.
2017,
Pubmed
Blazek,
The Cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes.
2011,
Pubmed
Bluemn,
Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling.
2017,
Pubmed
Boysen,
SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity.
2018,
Pubmed
Brastianos,
Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets.
2015,
Pubmed
Cancer Genome Atlas Research Network,
The Molecular Taxonomy of Primary Prostate Cancer.
2015,
Pubmed
Carver,
Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate.
2009,
Pubmed
Cerami,
The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data.
2012,
Pubmed
Chakravarty,
OncoKB: A Precision Oncology Knowledge Base.
2017,
Pubmed
Chang,
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
2016,
Pubmed
Conteduca,
Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study.
2017,
Pubmed
Cuzick,
Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort.
2012,
Pubmed
Dobin,
STAR: ultrafast universal RNA-seq aligner.
2013,
Pubmed
Epstein,
Proposed morphologic classification of prostate cancer with neuroendocrine differentiation.
2014,
Pubmed
Ertel,
RB-pathway disruption in breast cancer: differential association with disease subtypes, disease-specific prognosis and therapeutic response.
2010,
Pubmed
Hieronymus,
Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators.
2006,
Pubmed
Hussain,
Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012.
2018,
Pubmed
Ku,
Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance.
2017,
Pubmed
Mateo,
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.
2015,
Pubmed
Mateo,
Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study.
2018,
Pubmed
Mu,
SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer.
2017,
Pubmed
Nava Rodrigues,
RB1 Heterogeneity in Advanced Metastatic Castration-Resistant Prostate Cancer.
2019,
Pubmed
Pritchard,
Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer.
2016,
Pubmed
Quigley,
Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.
2018,
Pubmed
Robinson,
Integrative clinical genomics of advanced prostate cancer.
2015,
Pubmed
Robinson,
Integrative clinical genomics of metastatic cancer.
2017,
Pubmed
Romanel,
Plasma AR and abiraterone-resistant prostate cancer.
2015,
Pubmed
Scher,
Nuclear-specific AR-V7 Protein Localization is Necessary to Guide Treatment Selection in Metastatic Castration-resistant Prostate Cancer.
2017,
Pubmed
Shen,
FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing.
2016,
Pubmed
Taylor,
Integrative genomic profiling of human prostate cancer.
2010,
Pubmed
Viswanathan,
Structural Alterations Driving Castration-Resistant Prostate Cancer Revealed by Linked-Read Genome Sequencing.
2018,
Pubmed
Wu,
Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer.
2018,
Pubmed
